This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS
by Zacks Equity Research
MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.
QGEN Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
by Zacks Equity Research
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies
by Zacks Equity Research
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
by Zacks Equity Research
The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
IINN Stock Gains on Second US Patent Approval for VORTX System
by Zacks Equity Research
Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.
KIDS Stock Gains From Its New Enabling Technologies Division Launch
by Zacks Equity Research
OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.
PAHC Stock Gains From Innovation, Market Expansion Goal
by Zacks Equity Research
Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
by Zacks Equity Research
QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.
CVS Stock Gains From Its Birth Control Prescribing Service Launch
by Zacks Equity Research
CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
by Zacks Equity Research
Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.
Factors Driving Veeva Stock More Than 20% in Three Months
by Zacks Equity Research
Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.
Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece
by Zacks Equity Research
SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.
Owens & Minor Stock to Gain From New Collaboration With Google Cloud
by Zacks Equity Research
OMI announces partnership with Google Cloud to enhance existing QSight capabilities.
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Boston Scientific (BSX) stood at $82.94, denoting a -0.14% change from the preceding trading day.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?
by Urmimala Biswas
MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
by Zacks Equity Research
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
Glaukos Stocks Rides on Strong Product Demand Amid Competition
by Zacks Equity Research
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Reasons to Retain ResMed Stock in Your Portfolio for Now
by Zacks Equity Research
Strong demand for RMD's market-leading mask portfolio raises investors' optimism.
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
by Zacks Equity Research
Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
MASI Stock Down Despite New SafetyNet Deal for Neonatal Care
by Zacks Equity Research
The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.